Human Pluripotent Stem Cell-Derived Engineered Tissues: Clinical Considerations

Kelly R Stevens; Charles E Murry

doi:10.1016/j.stem.2018.01.015

Human Pluripotent Stem Cell-Derived Engineered Tissues: Clinical Considerations

Cell Stem Cell. 2018 Mar 1;22(3):294-297. doi: 10.1016/j.stem.2018.01.015.

Authors

Kelly R Stevens¹, Charles E Murry²

Affiliations

¹ Department of Bioengineering, University of Washington, Seattle, WA, USA; Department of Pathology, University of Washington, Seattle, WA, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA; Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA.
² Department of Bioengineering, University of Washington, Seattle, WA, USA; Department of Pathology, University of Washington, Seattle, WA, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA; Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA; Department of Medicine/Cardiology, University of Washington, Seattle, WA, USA. Electronic address: murry@uw.edu.

Abstract

The combined power of human pluripotent stem cells and tissue engineering promises to revolutionize medicine by building tissue patches and artificial replacement organs for patients battling diverse diseases. Here, we articulate some big questions that need to be addressed before such engineered tissues become mainstream in the clinic.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Goals
Humans
Morphogenesis
Pluripotent Stem Cells / cytology*
Tissue Engineering / methods*

Abstract

Publication types

MeSH terms

Grants and funding